Aphria buying at Scythian Biosciences (SCYB)

Aphria buying at Scythian Biosciences (C:SCYB)

Aphria Inc. (APH), a 10% Holder, acquired 123,800 Common Shares on a direct ownership basis at prices ranging from $2.351 to $2.477 between August 22 and 23rd, 2018. This represents a $296,625 investment into the company's shares and an account share holdings change of 18.4%.

Scythian Biosciences is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Scythian Biosciences Corp, formerly Kitrinor Metals Inc, is a Canada-based pre-clinical research and development company. It is engaged in the process of developing drug therapies. The Company conducts a project regarding development of a cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. The Company also provides a research in area of treatment of gastro-inflammatory disease.